Elemind develops a wearable neurotechnology platform that uses proprietary signal-processing algorithms and AI to read individual brainwaves and deliver tailored, real-time stimulation—an approach the company calls “electric medicine.” The company’s first product is positioned as a general wellness device and is expected to be revealed in the coming months. Elemind emerged from stealth after conducting research since 2019 and holds three critical patents covering its core algorithms and dynamic neurostimulation techniques. Its technology is supported by five clinical trials and multiple peer-reviewed publications (including Nature Communications) showing faster sleep induction (up to 74% faster), rapid suppression of essential tremor, memory boosts, increased pain thresholds, and enhanced sedation (the latter in peer review). The founding team includes neuroscientists and researchers affiliated with MIT, Imperial College London, Harvard Medical School, and UC Berkeley. The company plans to use the recently closed seed funding to further develop and validate its wearable product and build applications across neurological conditions.

Total raised

$12M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2024